In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.
A phase 2 exploratory study of men with low- and intermediate-risk localized prostate cancer demonstrated the oncologic benefit of enzalutamide treatment vs active surveillance.
Five-year survival rates following nephrectomy for renal cell carcinoma are higher among patients with favorable vs unfavorable histology.
A small randomized trial finds no worse satisfaction with telemedicine vs in-person visits among patients with OAB.
Greater consumption of healthful plant-based foods is associated with significantly reduced risks for advanced, lethal, and fatal prostate cancer, especially among men younger than 65 years.
Investigators report increased risks for adverse pathology and 90-day readmission.
In a single-center study, the median duration of percutaneous tibial nerve stimulation therapy was 147 days.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
In addition to similar rates of overall survival, patients undergoing partial and radical cystectomy had comparable rates of upstaging to pT3-4 disease.
The risk for alzheimer disease decreased with increased dosing of BCG.
A male-to-female gap decreased significantly over time among White and non-Hispanic stone formers, but not among Black stone formers.
A mitomycin-containing reverse thermal gel could provide an alternative to repetitive surgeries for low-grade intermediate-risk NMIBC, according to investigators.
New study findings “are critically important in patient counseling and surgical planning, particularly for patients with risk factors for renal deterioration,” according to investigators.
If validated, the EpiCheck® assay may identify more patients who can safely delay or avoid nephroureterectomy.
The risks for metastasis, biochemical recurrence, and overall mortality are unaffected, according to investigators.